# BioGeneration Ventures

> BioGeneration Ventures is a VC fund backing Biotechnology and Therapeutics. See 65 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Naarden, The Netherlands
- Total investments: 65
- Last investment: Aug 2026
- Lead investor: 28%
- Fund size: $148M
- Last fund: Jan 2021
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/biogeneration-ventures
- Website: http://www.biogenerationventures.com

BioGeneration Ventures is a VC fund in Naarden focused on Biotechnology and Therapeutics. BioGeneration Ventures is investing in the next generation of Life Sciences companies in the Netherlands. BioGeneration Ventures invests in Dutch start-up and early stage life sciences companies. The BioGeneration Ventures team is specialized in the evaluation and management of early stage companies. Their involvement goes beyond thefinancial investment. They work closely with scientists, academic institutions, entrepreneurs and industry experts to accelerate the development and to optimize the commercial potential of their portfolio company's technologies. BioGeneration Ventures began operating in 2006 and the fund is backed by the Netherlands Genomics Initiative (NGI) and the Netherlands Organisation for Scientific Research (NWO) in combination with the holding company of Leiden University and ABN-AMRO Capital as lead private investors.

## Contacts

5 contacts available for BioGeneration Ventures. Shizune tracks 7 team members at BioGeneration Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/biogeneration-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.1M–$50M |
| Series A | $5.3M–$86M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 31 | 48% |
| Therapeutics | 20 | 31% |
| Health Care | 17 | 26% |
| Medical | 12 | 18% |
| Pharmaceutical | 10 | 15% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 20 | 31% |
| Funding Round | 14 | 22% |
| Seed | 10 | 15% |
| Series B | 9 | 14% |
| Series C | 2 | 3% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| The Netherlands | 26 | 40% |
| United States | 7 | 11% |
| Belgium | 3 | 5% |
| United Kingdom | 3 | 5% |
| Germany | 2 | 3% |

7 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Daniela Couto | General Partner | 3 | https://shizune.co/investors/profile/daniela-couto |
| Edward van Wezel | Founder and Managing Partner | 8 | https://shizune.co/investors/profile/edward-van-wezel |
| Joost Holthuis | Venture Partner | 0 | https://shizune.co/investors/profile/joost-holthuis |
| Oskar Slotboom | Managing Partner | 6 | https://shizune.co/investors/profile/oskar-slotboom |
| Elena Ritsou | Venture Partner | 0 | https://shizune.co/investors/profile/elena-ritsou |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mironid | Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network. | $46M | Series B | Aug 05, 2026 |  |
| TargED Biopharmaceuticals | TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. | $25.3M | Series A | Dec 16, 2025 |  |
| Azafaros | Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. | $147.6M | Series B | May 13, 2025 |  |
| Avidicure | Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality.“AVC-Boosters”, designed to safely deliver targeted and potent monotherapy, with broad applicability in oncology. | $50M | Seed | Apr 24, 2025 |  |
| Rhygaze | Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness. | $86M | Series A | Jan 10, 2025 |  |
| Citryll | Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.Citryll was established in 2015 and is headquartered in Oss, The Netherlands. | $89.7M | Series B | Dec 09, 2024 |  |
| Kivu Bioscience | Kivu Bioscience is a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics and focused on rapidly advancing next generation transformative assets. | $92M | Series A | Oct 28, 2024 |  |
| Tanai Therapeutics | Tanai Therapeutics develops novel therapeutics for people living with obesity and obesity-related complications. | $3.5M | Seed | Sep 19, 2024 |  |
| Confo Therapeutics | Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. | $65.2M | Series B | Jul 26, 2024 |  |
| Brenig Therapeutics | Brenig Therapeutics develops therapies for neurodegenerative disorders. | $65M | Series A | Jul 24, 2024 |  |

10 of 65 investments shown.

## Co-investors
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 28 deals together
- [BOM](https://shizune.co/investors/profile/brabantse-ontwikkelings-maatschappij-bom) — VC Fund, 8 deals together
- [New Science Ventures](https://shizune.co/investors/profile/new-science-ventures) — VC Fund, 8 deals together
- [Inkef](https://shizune.co/investors/profile/inkef-capital) — VC Fund, 6 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 5 deals together
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 5 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Biotechnology VC Funds in Belgium](https://shizune.co/investors/biotechnology-vc-funds-belgium)
- [Biotech Investors in Belgium](https://shizune.co/investors/biotech-investors-belgium)
- [Biotech VC Funds in Belgium](https://shizune.co/investors/biotech-vc-funds-belgium)
- [Health Care Investors in Belgium](https://shizune.co/investors/health-care-investors-belgium)
- [Health Care VC Funds in Belgium](https://shizune.co/investors/health-care-vc-funds-belgium)
- [Medical VC Funds in Belgium](https://shizune.co/investors/medical-vc-funds-belgium)

## FAQ

### What does BioGeneration Ventures invest in?

BioGeneration Ventures invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Funding Round stage. Most of the 65 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is BioGeneration Ventures's check size?

BioGeneration Ventures typically joins rounds of $1.1M–$50M at Seed and $5.3M–$86M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BioGeneration Ventures participates in.

### How do I contact BioGeneration Ventures?

Public channels for BioGeneration Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at BioGeneration Ventures?

The team at BioGeneration Ventures includes Daniela Couto (General Partner), Edward van Wezel (Founder and Managing Partner) and Joost Holthuis (Venture Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co